Investor Presentaiton

17 Commercial execution and innovation Diabetes care Raising the innovation-bar for diabetes treatment Further raise the innovation bar for diabetes treatment Unmet need within diabetes remain large Moving towards patient outcomes beyond blood glucose lowering Developing differentiated next-generation injectable and oral GLP-1-based offerings Digital health to provide improved patient support and to achieve clinical trial results in the real world Novo NordiskⓇ Development pipeline 2022 2023 2024 2025 Semaglutide 2.0 mg, QW GLP-1 US regulatory feedback pending CagriSema, FDC QW incretin treatment Phase 2 Semaglutide+GIP, FDC QW incretin treatment Phase 2 Injectable incretins Semaglutide 1.0 mg in PAD Phase 3 Semaglutide 1.0 mg in diabetic retinopathy Semaglutide 1.0 mg in chronic kidney disease Oral semaglutide 25 mg and 50 mg Phase 3 Phase 3 Phase 3 Oral incretins SOUL, oral semaglutide 14 mg CVOT Icodec, QW basal insulin Phase 3 (indicative, event-driven) Phase 3 IcoSema, QW FDC basal insulin and GLP-1 Phase 3 Insulin projects Ideal Pump Insulin (type 1 diabetes) Phase 1 Glucose-sensitive insulin Phase 1 Other DNA Immunotherapy (type 1 diabetes) Phase 1 GIP: Gastric inhibitory polypeptide; FDC: Fixed-Dose Combination; QW: Once weekly; PAD: Peripheral arterial disease; CVOT: Cardiovascular outcome trial; cagri: Cagrilintide; sema: semaglutide; Ico: Icodec

View entire presentation